← Leaderboards
William C Raschke
Virogenics, Inc.
$15,775,674
Attributed
$21,222,306
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,222,306 · 13
By mechanism
R44$8,413,707 · 4
R01$6,362,537 · 2
U01$3,156,836 · 1
R43$1,911,801 · 5
R24$1,377,425 · 1
Top collaborators
- Pamela Anne Maher7 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposClinical TrialsBaseDosePreventSafetySeriesClinical ResearchCanis FamiliarisIn VivoMouse ModelIn VitroSmall MoleculePharmaceutical PreparationsGeneticS DiseaseDesignImmune SystemGene ExpressionPhase I Clinical TrialsFundingBrainProductionAffect
Grant awards (30)
Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for AD$1,562,187
U01 · FY2025 · AG · contact PI
Paving the Way to Phase 2 Trials of CMS121 for Alzheimer's Disease$2,432,649
R44 · FY2024 · AG · contact PI
Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for AD$1,594,649
U01 · FY2024 · AG · contact PI
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease$2,338,814
R01 · FY2022 · AG · contact PI
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease$251,666
R01 · FY2022 · AG · contact PI
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease$210,130
R01 · FY2022 · AG · contact PI
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease$2,503,169
R01 · FY2021 · AG · contact PI
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD$965,711
R44 · FY2020 · AI · contact PI
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD$967,956
R44 · FY2019 · AI · contact PI
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD$977,956
R44 · FY2018 · AI · contact PI
siRNA Modulation of the Immune Response$300,000
R43 · FY2014 · AI · contact PI
siRNA Modulation of the Immune Response$300,000
R43 · FY2013 · AI · contact PI
FIV Vectors for the Treatment of Hemophilia A$699,475
R44 · FY2012 · HL · contact PI
FIV Vectors for the Treatment of Hemophilia A$1,009,436
R44 · FY2011 · HL · contact PI
FIV Vectors for the Treatment of Hemophilia A$54,720
R44 · FY2011 · HL · contact PI
FIV Vectors for the Treatment of Hemophilia A$905,804
R44 · FY2010 · HL · contact PI
A Novel Immune Modulator/ Adjuvant for HIV Vaccines$299,657
R43 · FY2009 · AI · contact PI
A Novel Immune Modulator/ Adjuvant for HIV Vaccines$299,657
R43 · FY2008 · AI · contact PI
Non-Integrating FIV Vectors for HIV Vaccines$300,000
R43 · FY2007 · AI · contact PI
Hemophilia A: Intrathymic Delivery for Tolerance and Longterm Expression of FVIII$149,881
R43 · FY2007 · HL · contact PI
MOLECULAR ANALYSIS RESOURCE FOR PRIMARY HUMAN CANCERS$347,200
R24 · FY2003 · CA
GENETIC ANALYSIS OF REGULATION AND FUNCTION OF CD45$356,542
R01 · FY2002 · AI
MOLECULAR ANALYSIS RESOURCE FOR PRIMARY HUMAN CANCERS$347,200
R24 · FY2002 · CA
A Mini-Ad Vector for Treatment of Factor VIII Deficiency$25,000
R44 · FY2002 · HL
A Mini-Ad Vector for Treatment of Factor VIII Deficiency$375,000
R44 · FY2001 · HL
GENETIC ANALYSIS OF REGULATION AND FUNCTION OF CD45$357,448
R01 · FY2001 · AI
MOLECULAR ANALYSIS RESOURCE FOR PRIMARY HUMAN CANCERS$347,200
R24 · FY2001 · CA
COMPLEMENTARY ADENOVIRAL VECTORS FOR TREATMENT OF CANCER$262,606
R43 · FY2001 · CA
GENETIC ANALYSIS OF REGULATION AND FUNCTION OF CD45$344,768
R01 · FY2000 · AI
MOLECULAR ANALYSIS RESOURCE FOR PRIMARY HUMAN CANCERS$335,825
R24 · FY2000 · CA